Brise disclosed a licensing agreement with AbbVie covering two preclinical migraine programs, with potential payments totaling up to $757 million across development, regulatory, and commercial milestones. AbbVie will take on global development and commercialization, while Brise retains discovery responsibilities. The companies said the arrangement traces back to a 2024 signature and that Brise has already reached several near-term milestones. Brise’s most advanced asset mentioned in the context is BR005, an oral small molecule in Phase II/III development as an acute migraine treatment. The deal underscores how migraine drug discovery remains active with structured milestone-heavy partnering, particularly when sponsors aim to build multiple shots on goal ahead of competitive differentiation.